DMA.V - DiaMedica Therapeutics Inc.

YHD - YHD Delayed Price. Currency in USD
500,000.00
+1.16 (+0.00%)
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • DiaMedica Therapeutics to Present at the 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020
    Business Wire

    DiaMedica Therapeutics to Present at the 17th Annual Craig-Hallum Institutional Investor Conference on May 27, 2020

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 17th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, May 27, 2020. Management will be available to participate in one-on-one meetings. Meetings will take place virtually given the ongoing call for social distancing due to the Covid-19 pandemic. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.

  • DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study
    Business Wire

    DiaMedica Announces Positive Results in Top-Line Data From the Phase II ReMEDy Acute Ischemic Stroke Study

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for neurological disorders and chronic kidney disease, announced today that DM199, a drug intended to restore KLK1 levels and the body’s natural ability to regulate blood flow and reduce inflammation after an acute ischemic stroke (AIS), met primary safety and tolerability endpoints in the ReMEDy phase II study. Further, no DM199-related serious adverse events were noted in the study. According to top-line phase II results, there was also a demonstrated therapeutic effect in participants who received tissue plasminogen activator (tPA) prior to enrollment, but not in participants receiving mechanical thrombectomy.

  • DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study and Provides a Business Update and First Quarter 2020 Financial Results
    Business Wire

    DiaMedica Announces Positive Results in Top-Line Data from the Phase II ReMEDy Acute Ischemic Stroke Study and Provides a Business Update and First Quarter 2020 Financial Results

    DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological disorders, today announced positive top-line results from ReMEDy, its Phase II study in acute ischemic stroke (AIS), as well as provided a business update and financial results for the three months ended March 31, 2020. DiaMedica will host a conference call with slides tomorrow, May 14, 2020, at 7:00 a.m. Central Time to discuss its ReMEDy top-line data, business update and first quarter financial results. In conjunction with this release, DiaMedica also issued today a separate more detailed release on the ReMEDy top-line data.

  • Thomson Reuters StreetEvents

    Edited Transcript of DMA.V earnings conference call or presentation 24-Mar-20 12:00pm GMT

    Q4 2019 DiaMedica Therapeutics Inc Earnings Call